Moreover, APOE ε4 carriers progress more rapidly from mild cognitive impairment (MCI) to Alzheimer’s disease dementia than non-carriers [8], although the precise pathophysiology of this risk remains unclear. Here, APOE is linked to early-onset autosomal dominant Alzheimer disease.